RJ Tesi

Company: Inmune Bio

Job title: Chief Executive & Medical Officer

Seminars:

Resistance to Immunotherapy Caused by MUC4 Expression in HER2+ Tumors – Bench to Bedside 12:30 pm

• Exploring how MUC4 expression predicts resistance to immunotherapy • Targeting soluble TNF reverses resistance in animal models • Understand how knowing the MUC4 status of a patient’s tumor will improve clinical decision making and should benefit patient outcomeRead more

day: Day Two